Company news
Stemrim Inc. (TSE:4599) news
Stemrim Inc. news releases on 6ix. Latest, Oct 7, 2026: Notice Regarding US Patent Registration of SR-GT1 for Dystrophic Epidermolysis Bullosa
Press releases & updates
Notice Regarding US Patent Registration of SR-GT1 for Dystrophic Epidermolysis Bullosa
October 7, 2026
Patent Registration in South Korea for Redasemtide in Cartilage Disorders
September 25, 2026
StemRIM Announces Fixed Details of the Issuance of Stock Options to Employees
September 10, 2026
StemRIM Announces Issuance of Stock Acquisition Rights as Stock Options to Employees
September 9, 2026
StemRIM Announces Patent Registration for SR-GT1 Aimed at Curative Treatment of Dystrophic Epidermolysis Bullosa in South Korea
August 3, 2026
StemRIM Announces Patent Registration (Mexico) for Redasemtide, as an Additional Therapeutic Indication of Cartilage Disorders
July 22, 2026
StemRIM Announces Patent Registration (Canada) for Redasemtide, as an Additional Therapeutic Indication for Cardiomyopathy, Old Myocardial Infarction
July 13, 2026
StemRIM Announces Patent Registration for Stem Cell Gene Therapy Technology (SR-GT1) Aimed at Curative Treatment of DEB in ,South Korea
July 8, 2026
[Delayed]Notice Regarding Recognition of Non-operating Income (Subsidy Income)
June 18, 2026
StemRIM Announces Patent Registration (Australia) for Redasemtide, as an Additional Therapeutic Indication of Cartilage Disorders
June 17, 2026
StemRIM Announces Patent Registration (Russia) for Redasemtide, as a Therapeutic Indication for Fatty Liver and Non-alcoholic Steatohepatitis
June 16, 2026
Non-consolidated Financial Results for the Nine Months Ended April 30, 2026 [Japanese GAAP]
June 10, 2026